Rheumatology International

, Volume 27, Issue 11, pp 1063–1069

Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis

  • Manathip Osiri
  • Pirom Kamolratanakul
  • Andreas Maetzel
  • Peter Tugwell
Original Article

DOI: 10.1007/s00296-007-0342-5

Cite this article as:
Osiri, M., Kamolratanakul, P., Maetzel, A. et al. Rheumatol Int (2007) 27: 1063. doi:10.1007/s00296-007-0342-5

Abstract

The objective was to assess the cost-effectiveness of various DMARDs compared with antimalarials (AM) for rheumatoid arthritis (RA) treatment. The data on disease activity, functional status and societal costs were collected from a 1-year cohort of 152 patients with RA receiving at least one DMARD for ≥ 6 months. Incremental cost effectiveness ratio (ICER) was calculated from the societal costs of DMARD treatment compared with AM per one unit of HAQ improvement. All costs were presented in 2001 US dollars. Mean (SD) societal cost of AM treatment was US$ 2,285 (1,154) per patient per year. MTX + AM was less costly and more effective than AM, as the ICER of this combination would save US$ 834 per 1 U of HAQ improvement. MTX + SSZ, leflunomide, and triple therapy (AM + MTX + SSZ) were more effective than AM with additional costs. RA treatment with non MTX-based DMARDs was not cost-effective.

Keywords

Rheumatoid arthritisCost effectiveness analysisDisease modifying antirheumatic drugsHealth assessment questionnaire

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Manathip Osiri
    • 1
  • Pirom Kamolratanakul
    • 2
  • Andreas Maetzel
    • 3
  • Peter Tugwell
    • 4
  1. 1.Division of Rheumatology, Department of Medicine, Faculty of MedicineChulalongkorn UniversityBangkokThailand
  2. 2.Department of Preventive and Social Medicine, Faculty of MedicineChulalongkorn UniversityBangkokThailand
  3. 3.Division of Clinical Decision Making, Department of Health Policy, Management and EvaluationUniversity Health Network, University of TorontoTorontoCanada
  4. 4.Centre for Global Health, Institute of Population HealthUniversity of OttawaOttawaCanada